Lannett Company (NYSE:LCI) announces positive results from the first human study evaluating it and alliance partner HEC Group’s insulin glargine, a biosimilar to Sanofi’s (NASDAQ:SNY) top diabetes seller Lantus.
It plans to meet with the FDA in the coming months to clarify a registration path.
Lantus accounted for 60% of Sanofi’s Q3 diabetes sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.